Bio-Techne Corp
TECH50.240USD
-0.539-1.06%
Cierre 04/25, 16:00（ET）Cotizaciones retrasadas 15 min
7.93BCap. mercado
50.18P/E TTM
Más Datos de Bio-Techne Corp Compañía
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Información de la empresa
Código de la empresaTECH
Nombre de la empresaBio-Techne Corp
Fecha de salida a bolsaFeb 09, 1989
Fundada en1981
Director ejecutivoMr. Kim Kelderman
Número de empleados3100
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 09
Dirección614 Mckinley Pl N E
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55413
Teléfono16123798854
Sitio Webhttps://www.bio-techne.com/
Código de la empresaTECH
Fecha de salida a bolsaFeb 09, 1989
Fundada en1981
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
159.91M
53.83%
EMEA, excluding U.K
70.39M
23.70%
Greater China
24.75M
8.33%
APAC, excluding Greater China
19.01M
6.40%
United Kingdom
13.24M
4.46%
Rest of World
9.73M
3.27%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Accionista
Hora de actualización: vie., 21 de feb
Hora de actualización: vie., 21 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
47.40%
Investment Advisor
44.16%
Hedge Fund
2.25%
Bank and Trust
2.16%
Pension Fund
1.88%
Research Firm
1.54%
Sovereign Wealth Fund
1.27%
Individual Investor
1.04%
Insurance Company
0.23%
Participación institucional
Hora de actualización: lun., 20 de ene
Hora de actualización: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1193
162.20M
102.60%
-2.87M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
2022Q4
1190
153.16M
97.57%
-6.72M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
18.52M
11.72%
+275.81K
+1.51%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.43M
6.6%
+1.23M
+13.34%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.25M
5.85%
+4.60K
+0.05%
Dec 31, 2024
State Street Global Advisors (US)
6.47M
4.09%
+76.69K
+1.20%
Dec 31, 2024
Baron Capital Management, Inc.
4.14M
2.62%
-308.56K
-6.94%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.00M
2.53%
+98.66K
+2.53%
Dec 31, 2024
Neuberger Berman, LLC
3.58M
2.27%
+65.69K
+1.87%
Dec 31, 2024
D. F. Dent & Company, Inc.
3.20M
2.03%
-97.30K
-2.95%
Dec 31, 2024
Atlanta Capital Management Company, L.L.C.
2.95M
1.87%
-40.17K
-1.34%
Dec 31, 2024
Mairs and Power, Inc.
2.82M
1.78%
-24.98K
-0.88%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Global X Genomics & Biotechnology ETF
4.16%
Invesco Biotechnology & Genome ETF
2.26%
Tema Monopolies and Oligopolies ETF
1.9%
VanEck Biotech ETF
1.79%
Hilton Small-MidCap Opportunity ETF
1.77%
Thrivent Small-Mid Cap ESG ETF
1.75%
iShares Health Innovation Active ETF
1.72%
Neuberger Berman Small-Mid Cap ETF
1.49%
Invesco S&P 500 Equal Weight Health Care ETF
1.27%
American Century Mid Cap Growth Impact ETF
0.98%
Ver más
Global X Genomics & Biotechnology ETF
Proporción4.16%
Invesco Biotechnology & Genome ETF
Proporción2.26%
Tema Monopolies and Oligopolies ETF
Proporción1.9%
VanEck Biotech ETF
Proporción1.79%
Hilton Small-MidCap Opportunity ETF
Proporción1.77%
Thrivent Small-Mid Cap ESG ETF
Proporción1.75%
iShares Health Innovation Active ETF
Proporción1.72%
Neuberger Berman Small-Mid Cap ETF
Proporción1.49%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.27%
American Century Mid Cap Growth Impact ETF
Proporción0.98%
Dividendos
Un total de
249.41M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Nov 01, 2022
Split
1>4
Fecha
Tipo
Relación
Nov 01, 2022
Split
1>4